Russian scientists have developed a new method of obtaining isotopes for nuclear medicine, according to the Ministry of Science and Higher Education of Russia, TASS reports.
The new technology enables isotopes to be obtained directly in nuclear medicine centers, which reduces logistical costs and lowers the cost of proton cancer treatment.
Researchers from Tomsk State University (TSU) and the Lebedev Physical Institute (LPI) have proposed using the institute's Prometheus accelerator to produce molybdenum-99 isotopes, which in turn serves to produce technetium-99m, the main diagnostic radionuclide in modern nuclear medicine used not only for the production of molybdenum-99, but also for the production of other important isotopes—for example, lutetium-177 and rhenium-188, which are actively used in the treatment of cancer.
"We carried out a computer simulation of this process and showed that, taking into account the characteristics of the Prometheus accelerator, the efficiency of isotope production can be very high, especially for the molybdenum isotope. The simulation made it possible to determine the main parameters of the system. For example, it was found that the maximum efficiency is achieved with a target thickness of 1 millimeter, which enables to achieve high productivity with minimum material consumption," Vladimir Ivanchenko, a leading researcher at the High Energy Physics Data Analysis Laboratory of TSU, said in a statement.
The main advantage of this new technology is its versatility. Its installation enables the production of isotopes to be combined with the main functions of the accelerator; in particular, therapeutic use. This makes it possible to obtain the necessary isotopes directly in nuclear medicine treatment and diagnostic centers, reducing logistical costs and making high-tech medicine more affordable.
Follow NEWS.am Medicine on Facebook and Twitter
month
week
day